Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660
01/09/2026 11:10
BRIEF-Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660 Sept 1 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK:
ENTERS EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH ROCHE FOR SIM0660 ON SEPT 1, 2026
ELIGIBLE FOR TIERED ROYALTIES OF UP TO DOUBLE DIGITS ON FUTURE NET SALES
ELIGIBLE FOR $75 MILLION UPFRONT AND UP TO $1.46 BILLION IN MILESTONE PAYMENTS
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660